Scientists at the Wisconsin National Primate Research Center (WNPRC) and the Morgridge Institute for Research at the University of Wisconsin–Madison have been at the forefront of stem cell research ...

Rivaroxaban tablets are used to reduce the risk of major cardiovascular events in patients with CAD; to reduce the risk of major thrombotic vascular events in patients with PAD, including patients ...

Cardiovascular disease is a general term that refers to many different types of heart problems. Heart disease is the No. 1 ...

Are you experiencing leg pain, numbness, or slow-healing wounds? 🦵 These could be warning signs of Peripheral Artery Disease ...

Peripheral artery disease, also known as PAD, is a condition in which the narrowing of the arteries causes poor blood flow to ...

Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a ...

Johnson & Johnson MedTech‘s Shockwave Medical announced the U.S. launch of its Javelin peripheral intravascular lithotripsy ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday.

Johnson & Johnson MedTech’s Shockwave Medical is launching a new intravascular lithotripsy catheter in the U.S. | While ...

A scientific statement regarding pain and treatment considerations in patients with PAD has been published by the AHA.

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...